---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-014938"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:05:48.366383+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monopar Q3 net loss $2.4M ($0.19/share); cash $14.3M; Validive interim analysis Q1 2023

## Summary
- Net loss of $2.4M ($0.19 per share) vs. $2.5M ($0.20) in Q3 2021; R&D $1.73M, G&A $0.68M.
- Cash and equivalents $14.3M; expects to fund VOICE Phase 2b and camsirubicin Ph1b through Nov 2023.
- Validive VOICE trial: 73 active sites, >130 patients dosed; Phase 2b enrollment complete; Phase 3 enrollment started.
- Blinded interim analysis of Validive Phase 2b data expected to be reported in Q1 2023.
- Camsirubicin Ph1b data to be presented at CTOS Nov 16-19; MNPR-202 preclinical data at ASH Dec 10-13.

## SEC filing metadata
- accession: 0001654954-22-014938
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000165495422014938/0001654954-22-014938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000165495422014938/mnpr_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-014938
- JSON: https://secwatch.observer/filing/0001654954-22-014938.json
- Plain text: https://secwatch.observer/filing/0001654954-22-014938.txt

## Key facts
- Earnings Releases
  Monopar Therapeutics reported third quarter ended September 30, 2022 results: net income $2.4 million or $0.19 per share, EPS $0.19 per share.
  - Period: third quarter ended September 30, 2022
  - Net income: $2.4 million or $0.19 per share
  - EPS: $0.19 per share
  - Result: reported results
  source text: Monopar Therapeutics Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000165495422014938/0001654954-22-014938-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.